Palmitoylethanolamide Opioid Combination for Tolerance Delay
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of tolerance to opioids, such as morphine, limits their long-term effectiveness in pain management due to increased dosing requirements, leading to adverse effects like sedation and respiratory depression, and existing treatments fail to effectively delay this tolerance.
Innovation Solution
The use of palmitoylethanolamide (PEA) in micronized or ultra-micronized form, combined with opioids, significantly reduces glial cell activation in the spinal cord and brain, thereby delaying the onset of opioid tolerance, prolonging the analgesic effect when administered separately or in combination with opioids like morphine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioids are administered continuously for pain management, then analgesic effect is maintained, but tolerance develops requiring dose increases
Solution Approach 1:
The patent applies preliminary action by administering PEA before or during opioid treatment to prevent glial cell activation before it can occur. This proactive approach delays tolerance development and extends the duration of opioid analgesic effect without requiring dose increases.
Solution Approach 2:
PEA acts as an intermediary substance that modulates the interaction between opioids and glial cells. By introducing PEA as a mediator, the patent prevents the harmful activation of glial cells that would otherwise lead to tolerance, thereby extending the effective duration of opioid treatment.
2Reliability
If opioid dose is increased to overcome tolerance, then analgesic effect is maintained, but adverse effects increase
Solution Approach 1:
The patent converts the harmful effect of glial cell activation into a beneficial outcome by using PEA to prevent this activation. Instead of allowing tolerance to develop (harm) and then increasing doses (more harm), PEA prevents the initial harm, enabling maintenance of effective analgesia without adverse effects.
Solution Approach 2:
PEA serves as a protective intermediary that blocks the pathway from opioid administration to glial cell activation. This intermediary role prevents the cascade leading to tolerance and subsequent adverse effects from dose increases.
3Ease of operation
If PEA is administered in non-micronized form, then treatment is simpler, but bioavailability and efficacy are reduced
Solution Approach 1:
The patent applies parameter changes by modifying the physical state of PEA from non-micronized to micronized or ultra-micronized forms. This change in particle size parameter dramatically improves bioavailability and efficacy while maintaining the simplicity of oral or parenteral administration.
Solution Approach 2:
The patent uses composite material approaches by formulating PEA in micronized or ultra-micronized forms, which may involve composite particle structures that enhance solubility and absorption while preserving the core active ingredient's properties.
Data Source
Figure 1
AI summary
This invention relates to a pharmaceutical composition for human or animal use containing N-palmitoylethanolamide as an analgesic in combination with opioids. In particular, this invention relates to palmitoylethanolamide in non-micronized form, in micronized form (PEA-m), in ultra-micronized form (PEA-um) or mixtures thereof, for use in humans or animals in combination with an opioid in the treatment of pain conditions, wherein said palmitoylethanolamide is administered separately, sequentially, or in combination with said opioid.